Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : Conference call regarding updated 2020 outlook 9 October 2020

10/12/2020 | 09:55am EST

Novo Nordisk

  • a focused healthcare company

Conference call regarding updated 2020 outlook 9 October 2020

2

Novo Nordisk®

Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company's statutory Annual Report 2019 and Form 20-F, which are both expected to be filed with the SEC in February 2020 in continuation of the publication of the Annual Report 2019, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

  • Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,
  • Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,
  • Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
  • Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in this presentation, reference is made to the overview of risk factors in 'Managing risks to protect value' on pp 33-35 of the Annual Report 2019.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise.

3

Novo Nordisk®

Novo Nordisk has raised 2020 outlook for sales and operating profit growth

Financial performance YTD 2020

9M 2020

3Q 2020

Sales growth

7%

7%

(CER)

Operating profit

7%

7%

growth (CER)

Outlook for 2020

Expectations 8 Oct

Expectations 6 Aug

Sales growth

5% to 8%

3% to 6%

(CER)

Operating profit

5% to 8%

2% to 5%

growth (CER)

4

Novo Nordisk®

The financial performance reflects lower than anticipated negative impacts from COVID-19

Key developments

Sales growth Business performance

  • 7% sales growth in the first nine months of 2020
  • Solid momentum in GLP-1
  • Continuation of the H1 2020 growth trends in International Operations and North America Operations
  • Stocking at patient level has positively impacted year to date and destocking is expected to impact the remainder of 2020 and 2021

COVID-19 impacts

• The rise in US unemployment has an unfavourable impact on US channel mix

TRx development has been persistent despite fewer new patients initiating treatment

Operating profit growth

7% operating profit growth in the first nine months of 2020 driven by sales growth

5

Novo Nordisk®

Investor contact information

Share information

Novo Nordisk's B shares are listed on the stock exchange in Copenhagen under the symbol 'NOVO B'. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.

For further company information, visit Novo Nordisk on: www.novonordisk.com

Upcoming events

30 Oct 2020 Financial statement for the first nine months of 2020

03 Feb 2021 Financial statement for the full year of 2020

Investor Relations contacts

Novo Nordisk A/S

Investor Relations

Novo Allé

DK-2880 Bagsværd

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Valdemar Borum Svarrer

+45 3079 0301

jvls@novonordisk.com

Ann Søndermølle Rendbæk

+45 3075 2253

arnd@novonordisk.com

Mark Joseph Root

+45 3079 4211

mjhr@novonordisk.com

Kristoffer Due Berg (USA)

+1 609 235 2989

krdb@novonordisk.com

Q&A

Conference call regarding updated 2020 outlook 9 October 2020

Disclaimer

Novo Nordisk A/S published this content on 09 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2020 13:54:00 UTC


© Publicnow 2020
All news about NOVO NORDISK A/S
07:30aNOVO NORDISK A/S : files for US FDA regulatory approval of once-weekly semagluti..
AQ
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
More news
Financials
Sales 2020 127 B 20 833 M 20 833 M
Net income 2020 42 166 M 6 896 M 6 896 M
Net cash 2020 8 472 M 1 385 M 1 385 M
P/E ratio 2020 22,8x
Yield 2020 2,18%
Capitalization 955 B 156 B 156 B
EV / Sales 2020 7,43x
EV / Sales 2021 6,98x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 412,85 DKK
Spread / Highest target 32,0%
Spread / Average Target 6,50%
Spread / Lowest Target -29,8%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S6.78%155 973
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071